TCT-86 Real-World 30-Day Outcomes for the SAPIEN 3 Ultra Resilia Transcatheter Heart Valve in the Treatment of Failed Bioprosthetic Mitral Valves: A Propensity-Matched Analysis
Recommended Citation
Frisoli T, Eleid M, Krishnaswamy A, Kapadia S, Yadav P, Rajagopal V, Makkar R, Stinis C, Chetcuti S, Morse M, Frangieh A, Abbas A, Whisenant B, Guerrero M, Rodriguez E, Ailawadi G, O'Neill W. TCT-86 Real-World 30-Day Outcomes for the SAPIEN 3 Ultra Resilia Transcatheter Heart Valve in the Treatment of Failed Bioprosthetic Mitral Valves: A Propensity-Matched Analysis. J Am Coll Cardiol 2024; 84(18):B234.
Document Type
Conference Proceeding
Publication Date
10-29-2024
Publication Title
J Am Coll Cardiol
Abstract
Background: Mitral valve in valve (VIV) is safe and effective for severe bioprosthetic mitral degeneration, and associated with high one year survival rates. Little is known about the hemodynamic performance of the newest-generation Resilia SAPIEN 3 Ultra valve when used for mitral VIV. Methods: Retrospective analysis of patients undergoing transseptal mitral VIV with SAPIEN 3 valve family for failed surgical bioprostheses from 2021 through 2023 in the TVT Registry database with CMS data linkage was performed. 1,004 patients were studied in a 1:1 propensity matched analysis comparing Resilia vs non-Resilia valves with adjustment done for various covariates, including balloon valve fracture, predilatation and postdilatation. The primary outcome was echocardiographic mean gradient (MG) at 30 days. Results: Of the 1,004 patients studied, 48, 354, and 602 received 23-, 26-, and 29-mm valves, respectively. The mean age was 70.7 years, mean STS was 8.5, and 56.7% were women. Thirty-day mortality was similar for Resilia vs non-Resilia valves regardless of valve size (3.4% vs 3.8% for the overall cohort; P = 0.8, 4.2% vs 0%; P = 0.3 for 23 mm, 3.0% vs 3.5%; P = 0.8 for 26 mm, and 3.5% vs 4.2%; P = 0.0.7 for 29 mm). Kansas City Cardiomyopathy Questionnaire score at 30 days was also similar between groups regardless of valve size. Echocardiographic MG at 30 days was lower for Resilia vs non-Resilia for all valve sizes (Figure 1) [Formula presented] Conclusion: Resilia valves were associated with similar clinical outcomes following MVIV compared with non-Resilia valves, but with lower echo-derived gradients at 30 days. Categories: STRUCTURAL: Valvular Disease: Mitral.
Volume
84
Issue
18
First Page
B234
